Endoscopic surgery compared with intensity-modulated radiotherapy in resectable locally recurrent nasopharyngeal carcinoma: a multicentre, open-label, randomised, controlled, phase 3 trial

被引:105
|
作者
Liu, You-Ping [1 ,2 ]
Wen, Yi-Hui [1 ]
Tang, Jun [4 ]
Wei, Yi [1 ]
You, Rui [2 ]
Zhu, Xiao-Lin [1 ]
Li, Jian [1 ]
Chen, Lin [1 ]
Ling, Li [6 ,7 ]
Zhang, Ning [5 ]
Zou, Xiong [2 ]
Hua, Yi-Jun [2 ]
Chen, You-Mou [4 ]
Chen, Lei [3 ]
Lu, Li-Xia [3 ]
Chen, Ming-Yuan [2 ]
Wen, Wei-Ping [1 ,8 ]
机构
[1] Sun Yat Sen Univ, Otorhinolaryngol Inst, Affiliated Hosp 1, Guangzhou Key Lab Otorhinolaryngol,Dept Otolaryng, Guangzhou 510080, Peoples R China
[2] Sun Yat Sen Univ, State Key Lab Oncol South China,Canc Ctr, Collaborat Innovat Ctr Canc Med,Dept Nasopharynge, Guangdong Key Lab Nasopharyngeal Carcinoma Diag &, Guangzhou, Peoples R China
[3] Sun Yat Sen Univ, State Key Lab Oncol South China,Canc Ctr, Collaborat Innovat Ctr Canc Med,Dept Radiat Oncol, Guangdong Key Lab Nasopharyngeal Carcinoma Diag &, Guangzhou, Peoples R China
[4] First Peoples Hosp Foshan, Dept Otolaryngol, Foshan, Peoples R China
[5] First Peoples Hosp Foshan, Dept Radiat Oncol, Foshan, Peoples R China
[6] Sun Yat Sen Univ, Dept Med Stat, Sch Publ Hlth, Guangzhou, Peoples R China
[7] Sun Yat Sen Univ, Ctr Migrant Hlth Policy, Guangzhou, Peoples R China
[8] Sun Yat Sen Univ, Affiliated Hosp 6, Dept Otolaryngol, Guangzhou, Peoples R China
来源
LANCET ONCOLOGY | 2021年 / 22卷 / 03期
基金
中国国家自然科学基金;
关键词
3-DIMENSIONAL CONFORMAL RADIOTHERAPY; CONCURRENT CHEMORADIOTHERAPY; RADIATION-THERAPY; CHEMOTHERAPY; REIRRADIATION; CANCER; EVENTS;
D O I
10.1016/S1470-2045(20)30673-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background The role of surgery compared with reirradiation in the primary treatment of patients with resectable, locally recurrent nasopharyngeal carcinoma (NPC) who have previously received radiotherapy is a matter of debate. In this trial, we compared the efficacy and safety outcomes of salvage endoscopic surgery versus intensity-modulated radiotherapy (IMRT) in patients with resectable locally recurrent NPC. Methods This multicentre, open-label, randomised, controlled, phase 3 trial was done in three hospitals in southern China. We included patients aged 18-70 years with a Karnofsky Performance Status score of at least 70 who were histopathologically diagnosed with undifferentiated or differentiated, non-keratinising, locally recurrent NPC with tumours confined to the nasopharyngeal cavity, the post-naris or nasal septum, the superficial parapharyngeal space, or the base wall of the sphenoid sinus. Eligible patients were randomly assigned (1:1) to receive either endoscopic nasopharyngectomy (ENPG group) or IMRT (IMRT group). Randomisation was done manually using a computer-generated random number code and patients were stratified by treatment centre. Treatment group assignment was not masked. The primary endpoint was overall survival, compared between the groups at 3 years. Efficacy analyses were done by intention to treat. Safety analysis was done in patients who received treatment according to the treatment they actually received. This trial was prospectively registered at the Chinese Clinical Trial Registry, ChiCTRTRC-11001573, and is currently in follow-up. Findings Between Sept 30, 2011, and Jan 16, 2017, 200 eligible patients were randomly assigned to receive either ENPG (n=100) or IMRT (n=100). At a median follow-up of 56.0 months (IQR 42.0-69.0), 74 patients had died (29 [29%] of 100 patients in the ENPG group and 45 [45%] of 100 patients in the IMRT group). The 3-year overall survival was 85.8% (95% CI 78.9-92.7) in the ENPG group and 68.0% (58.6-77.4) in the IMRT group (hazard ratio 0.47, 95% CI 0.29-0.76; p=0.0015). The most common grade 3 or worse radiation-related late adverse event was pharyngeal mucositis (in five [5%] of 99 patients who underwent ENPG and 26 [26%] of 101 patients who underwent IMRT). Five [5%] of the 99 patients who underwent ENPG and 20 [20%] of the 101 patients who underwent IMRT died due to late toxic effects specific to radiotherapy; attribution to previous radiotherapy or trial radiotherapy is unclear due to the long-term nature of radiation-related toxicity. Interpretation Endoscopic surgery significantly improved overall survival compared with IMRT in patients with resectable locally recurrent NPC. These results suggest that ENPG could be considered as the standard treatment option for this patient population, although long-term follow-up is needed to further determine the efficacy and toxicity of this strategy. (C) 2021 Elsevier Ltd. All rights reserved.
引用
收藏
页码:381 / 390
页数:10
相关论文
共 50 条
  • [31] Pembrolizumab with or without bevacizumab in platinum- resistant recurrent or metastatic nasopharyngeal carcinoma: a randomised, open-label, phase 2 trial
    Chong, Wan-Qin
    Low, Jia-Li
    Tay, Joshua K.
    Le, Thi Bich Uyen
    Goh, Grace Shi-Qing
    Sooi, Kenneth
    Teo, Hui-Lin
    Cheo, Seng-Wee
    Wong, Regina Tong-Xin
    Samol, Jens
    Lim, Ming-Yann
    Li, Hao
    Shirgaonkar, Niranjan
    Chia, Shumei
    Wang, Lingzhi
    Gopinathan, Anil
    Eu, Donovan Kum-Chuen
    Tsang, Raymond King-Yin
    Loh, Kwok-Seng
    Toh, Han-Chong
    Syn, Nicholas
    Kong, Li-Ren
    Dasgupta, Ramanuj
    Tai, Bee-Choo
    Lim, Yaw-Chyn
    Goh, Boon-Cher
    LANCET ONCOLOGY, 2025, 26 (02): : 175 - 186
  • [32] Surgery versus conservative management for recurrent and ongoing left-sided diverticulitis (DIRECT trial): an open-label, multicentre, randomised controlled trial
    van de Wall, Bryan J. M.
    Stam, Marguerite A. W.
    Draaisma, Werner A.
    Stellato, R.
    Bemelman, Willem A.
    Boermeester, Marja A.
    Broeders, Ivo A. M. J.
    Belgers, Eric J.
    Toorenvliet, Boudewijn R.
    Prins, Hubert A.
    Consten, Esther C. J.
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2017, 2 (01): : 13 - 22
  • [33] Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial (vol 388, pg 1883, 2016)
    Zhang, L.
    Huang, Y.
    Hong, S.
    LANCET, 2016, 388 (10054): : 1882 - 1882
  • [34] A Phase II trial of Higher RadiOtherapy Dose In The Eradication of early rectal cancer (APHRODITE): protocol for a multicentre, open-label randomised controlled trial
    Hudson, Eleanor M.
    Noutch, Samantha
    Brown, Sarah
    Adapala, Ravi
    Bach, Simon P.
    Burnett, Carole
    Burrage, Alwyn
    Gilbert, Alexandra
    Hawkins, Maria
    Howard, Debra
    Jefford, Monica
    Kochhar, Rohit
    Saunders, Mark
    Seligmann, Jenny
    Smith, Alexandra
    Teo, Mark
    Webb, Edward J. D.
    Webster, Amanda
    West, Nicholas
    Sebag-Montefiore, David
    Gollins, Simon
    Appelt, Ane L.
    BMJ OPEN, 2022, 12 (04):
  • [35] Bevacizumab versus placebo in combination with paclitaxel and carboplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase II trial
    Zhou, T.
    Yang, Y.
    Ma, S.
    Lin, L.
    Zhou, T.
    Zhang, C.
    Ding, X.
    Wang, R.
    Feng, G.
    Chen, Y.
    Xu, R.
    Huang, Y.
    Zhang, L.
    ESMO OPEN, 2021, 6 (06)
  • [36] Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial
    Vilgrain, Valerie
    Pereira, Helena
    Assenat, Eric
    Guiu, Boris
    Ilonca, Alina Diana
    Pageaux, Georges-Philippe
    Sibert, Annie
    Bouattour, Mohamed
    Lebtahi, Rachida
    Allaham, Wassim
    Barraud, Helene
    Laurent, Valerie
    Mathias, Elodie
    Bronowicki, Jean-Pierre
    Tasu, Jean-Pierre
    Perdrisot, Remy
    Silvain, Christine
    Gerolami, Rene
    Mundler, Olivier
    Seitz, Jean-Francois
    Vidal, Vincent
    Aube, Christophe
    Oberti, Frederic
    Couturier, Olivier
    Brenot-Rossi, Isabelle
    Raoul, Jean-Luc
    Sarran, Anthony
    Costentin, Charlotte
    Itti, Emmanuel
    Luciani, Alain
    Adam, Rene
    Lewin, Maite
    Samuel, Didier
    Ronot, Maxime
    Dinut, Aurelia
    Castera, Laurent
    Chatellier, Gilles
    LANCET ONCOLOGY, 2017, 18 (12): : 1624 - 1636
  • [37] Volume and Dosimetric Variations During Two-Phase Adaptive Intensity-Modulated Radiotherapy for Locally Advanced Nasopharyngeal Carcinoma
    Wang, Rui-hao
    Zhang, Shu-xu
    Zhou, Ling-hong
    Zhang, Guo-qian
    Yu, Hui
    Lin, Xiao-dan
    Lin, Shengqu
    BIO-MEDICAL MATERIALS AND ENGINEERING, 2014, 24 (01) : 1217 - 1225
  • [38] Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial
    Yau, Thomas
    Park, Joong-Won
    Finn, Richard S.
    Cheng, Ann-Lii
    Mathurin, Philippe
    Edeline, Julien
    Kudo, Masatoshi
    Harding, James J.
    Merle, Philippe
    Rosmorduc, Olivier
    Wyrwicz, Lucjan
    Schott, Eckart
    Choo, Su Pin
    Kelley, Robin Kate
    Sieghart, Wolfgang
    Assenat, Eric
    Zaucha, Renata
    Furuse, Junji
    Abou-Alfa, Ghassan K.
    El-Khoueiry, Anthony B.
    Melero, Ignacio
    Begic, Damir
    Chen, Gong
    Neely, Jaclyn
    Wisniewski, Tami
    Tschaika, Marina
    Sangro, Bruno
    LANCET ONCOLOGY, 2022, 23 (01): : 77 - 90
  • [39] Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial
    Birtle, Alison
    Johnson, Mark
    Chester, John
    Jones, Robert
    Dolling, David
    Bryan, Richard T.
    Harris, Christopher
    Winterbottom, Andrew
    Blacker, Anthony
    Catto, James W. F.
    Chakraborti, Prabir
    Donovan, Jenny L.
    Elliott, Paul Anthony
    French, Ann
    Jagdev, Satinder
    Jenkins, Benjamin
    Keeley, Francis Xavier, Jr.
    Kockelbergh, Roger
    Powles, Thomas
    Wagstaff, John
    Wilson, Caroline
    Todd, Rachel
    Lewis, Rebecca
    Hall, Emma
    LANCET, 2020, 395 (10232): : 1268 - 1277
  • [40] Stereotactic body radiotherapy versus conventional external beam radiotherapy in patients with painful spinal metastases: an open-label, multicentre, randomised, controlled, phase 2/3 trial
    Sahgal, Arjun
    Myrehaug, Sten D.
    Siva, Shankar
    Masucci, Giuseppina L.
    Maralani, Pejman J.
    Brundage, Michael
    Butler, James
    Chow, Edward
    Fehlings, Michael G.
    Foote, Mathew
    Gabos, Zsolt
    Greenspoon, Jeffrey
    Kerba, Marc
    Lee, Young
    Liu, Mitchell
    Liu, Stanley K.
    Thibault, Isabelle
    Wong, Rebecca K.
    Hum, Maaike
    Ding, Keyue
    Parulekar, Wendy R.
    LANCET ONCOLOGY, 2021, 22 (07): : 1023 - 1033